Intermediate-term results of image-guided brachytherapy and high-technology external beam radiotherapy in cervical cancer: Chiang Mai University experience

Tharavichitkul, Ekkasit; Chakrabandhu, Somvilai; Wanwilairat, Somsak; Tippanya, Damrongsak; Nobnop, Wannapha; Pukanhaphan, Nantaka; Galalae, Razvan; Chitapanarux, Imjai

doi:10.1016/j.ygyno.2013.04.018

Cited by 27 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 14 ] 2012 117 CT (82%), MRI (18%) 24 79% (2-year) 3% Tharavichitkul et al . [ 15 ] 2013 47 CT (68%), MRI (32%) 26 98% 2% Lindegaard et al . [ 16 ] 2013 140 MRI 36 91% (3-year) 3% (GI tract), 1% (urinary tract) Dyk et al .…”

Section: Discussionmentioning

confidence: 99%

In-room computed tomography–based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study

Ohno

Noda

Okonogi

et al. 2016

Journal of Radiation Research

View full text Add to dashboard Cite

Herein, we investigate the long-term clinical outcomes for cervical cancer patients treated with in-room computed tomography–based brachytherapy. Eighty patients with Stage IB1–IVA cervical cancer, who had undergone treatment with combined 3D high-dose rate brachytherapy and conformal radiotherapy between October 2008 and May 2011, were retrospectively analyzed. External beam radiotherapy (50 Gy) with central shielding after 20–40 Gy was performed for each patient. Cisplatin-based chemotherapy was administered concurrently to advanced-stage patients aged ≤75 years. Brachytherapy was delivered in four fractions of 6 Gy per week. In-room computed tomography imaging with applicator insertion was performed for treatment planning. Information from physical examinations at diagnosis, and brachytherapy and magnetic resonance imaging at diagnosis and just before the first brachytherapy session, were referred to for contouring of the high-risk clinical target volume. The median follow-up duration was 60 months. The 5-year local control, pelvic progression-free survival and overall survival rates were 94%, 90% and 86%, respectively. No significant differences in 5-year local control rates were observed between Stage I, Stage II and Stage III–IVA patients. Conversely, a significant difference in the 5-year overall survival rate was observed between Stage II and III–IVA patients (97% vs 72%; P = 0.006). One patient developed Grade 3 late bladder toxicity. No other Grade 3 or higher late toxicities were reported in the rectum or bladder. In conclusion, excellent local control rates were achieved with minimal late toxicities in the rectum or bladder, irrespective of clinical stage.

show abstract

Section: Discussionmentioning

confidence: 99%

In-room computed tomography–based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study

Ohno

Noda

Okonogi

et al. 2016

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…IGABT (with repetitive MRI regarded as the gold standard) is increasingly replacing 2D brachytherapy throughout the world, especially in Europe [5] and North America [6] , but also in many places in Asia [7] , [8] . The Gyn GEC-ESTRO Recommendations I-IV have been used as the conceptual framework for the implementation of IGABT worldwide, and have been embedded and further developed in the new ICRU report 89 [9] .…”

Section: Development Of Image Guided Adaptive Brachytherapy: the Gec-mentioning

confidence: 99%

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies

Pötter

Tanderup

Kirisits

et al. 2018

Clinical and Translational Radiation Oncology

496

441

View full text Add to dashboard Cite

show abstract

“…In order to estimate the individual tumor control (TC) and OAR toxicity in this study, long term outcomes based on IGABT technique published by different institutions [12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22] were utilized to model the three-year local tumor control rate (3-yr LC) and three-year cancer specific survival rate (3-yr CSS). To reduce the variation within the data set, IGABT technique was used as inclusion criteria and data from more than 30% of patients who were stage IIA or less was excluded [12, 13, 22].…”

Section: Methodsmentioning

confidence: 99%

Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy

Kuo

Mehta

Yaparpalvi

et al. 2016

jcb

View full text Add to dashboard Cite

PurposeThis study assessed the modeled probability of tumor control and organ at risk toxicities in locally advanced cervical cancer in patients treated by external beam radiation plus brachytherapy using intracavitary combined with interstitial brachytherapy (IC/IS) vs. intracavitary brachytherapy (IC) alone.Material and methodsTwenty cervical cancer patients with a mean HR-CTV volume of 47.4 cm3 and a mean width of 54 mm were planned with both IC/IS and IC brachytherapy alone. A probit model was utilized to model 3-year (3-yr) local control rate (LC), 3-yr cancer specific survival rate (CSS), and the adverse effect (AE) of the organ at risk by using a modeled data set from multiple institutions. Modeling results were used to estimate the LC, CSS, and AE of the treatments in this study.ResultsUsing the IC/IS technique, an EQD2 increase of 12.3 Gy to D90 (from 76.1 Gy to 88.3 Gy) of HR-CTV is expected to increase 3-yr LC and 3-yr CSS by 12.5%, and 11.0%, respectively. Comparing IC/IS to IC alone, the expected G2+ AE were 7.7% vs. 7.9% for the bladder, and 5.9% vs. 6.8% for the rectum.ConclusionsThe IC/IS technique improved dose coverage to the HR-CTV without significantly increasing dose to 2 cm3 of the organ at risk (OAR) surrounding it. With different regimens of EBRT combined with BT, IC/IS can be used to increase the probability of LC and CSS, or decrease the risk of AE.

show abstract

Intermediate-term results of image-guided brachytherapy and high-technology external beam radiotherapy in cervical cancer: Chiang Mai University experience

Cited by 27 publications

References 28 publications

In-room computed tomography–based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study

In-room computed tomography–based brachytherapy for uterine cervical cancer: results of a 5-year retrospective study

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies

Model assessment of individual tumor control rate and adverse effects in comparing locally advanced cervical cancer treatment using intracavitary with and without interstitial brachytherapy

Contact Info

Product

Resources

About